Scheduling chemotherapy: Catch 22 between cell kill and resistance evolution

Journal of Theoretical Medicine

Volumn 2, Issue 3, 2000, Pages 215-232

  Gardner, Shea N ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Cell cycle phase specific; Chemotherapy; Continuous infusion; Drug kinetics; Gene amplification; Resistance evolution

Indexed keywords

ANTINEOPLASTIC AGENT; METHOTREXATE;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE PHASE; CELL DIVISION; CELL KILLING; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SPECIFICITY; GENE AMPLIFICATION; GROWTH RATE; HUMAN; LONG TERM EXPOSURE; MATHEMATICAL MODEL; MOLECULAR EVOLUTION; TUMOR GROWTH; TUMOR VOLUME;

EID: 0034587488     PISSN: 10273662     EISSN: None     Source Type: Journal    
DOI: 10.1080/10273660008833047     Document Type: Article

References (81)

1. Agur, Z. (1998). Resonance and anti-resonance in the design of chemotherapeutic protocols. J. Theoret. Med., 1, 237-245.
2. Anderson, H.. Prendiville, J., Thatcher, N., Radford, J. A. and Swindell, R. (199 1). A randomized study of intravenous bolus versus continuous infusion of ifosfamide and doxorubicin with oral etoposide for small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 117, S139-S140.
3. Antman, K. H., Ryan. L., Elias, A., Sherman, D. and Grier, H. E. (1989). Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. Journal of Clinical Oncology, 7, 126-131.
4. Bezwoda, W. R., Seymour, L. and Dansey, R. D. (1995). High-dose chemotherapy with hematopoietic rescue as primary treatment for metastic breast cancer: a randomized trial. Journal of Clinicol Oncology, 13, 2483-2489.
5. Birkhead, B. G., Rankin, E. M., Gallivan, S., Dones, L. and Rubens. R. D. (1987). A mathematical model of the development of drug resistance to cancer chemotherapy. European Journal of Cancer Clinical Oncology, 23, 1421-1427.
6. Bleyer, W. A., Poplack, D. G. and Simon, R. M. (1978). "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood, 51, 835-842.
7. Bodey, B., Bodey, B. Jr., Groger. A. M., Luck, J. V., Siegel, S. E., Taylor, C. R. and Kaiser, H. E. (1997). Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance. Anticancer Research, 17, 1311-1318.
8. Bruce, W. R., Meeker, R. E. and Valeriote, F. A. (1966). Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. Journal of the National Cancer Institute, 37, 233-245.
9. Campisi. C., Fabi. A., Papaldo, P., Tomao, S., Massidda, B., Zappala, A., Ionta, M. T. and Cognetti, F. (1998). Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A phase I-II clinical trial. Annals Of Oncology, 9, 565-567.
10. Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet, R., Adenis, A., Herait, P., Lokiec, F. and Mathieu-Bone, A. (1996). Pharmacokinetics and pharmacodynamics of irinotecan during a Phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Journal of the National Cancer Institute (Bethesda), 14, 2688-2695.
11. Cardman, M. D., Schornagel, J. H., Rivest, R. S., Srimatkandada, S., Portlock, C. S., Duffy, T. and Bertino, J. R. (1984). Resistance to methotrexate due to gene amplification in a patient with acute leukemia. Journal of Clinical Oncology, 2, 16-20.
12. Cojocaru, L. and Agur, Z. (1992). A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs. Mathematical Biosciences, 109, 85-97.
13. Coldman, A. J. and Goldie, J. H. (1987a). Impact of dose-intense chemotherapy on the development of permanent drug resistance. Seminars in Oncology, 14, 29-33.
14. Coldman, A. J. and Goldie, J. H. (1987b). Modeling resistance to cancer chemotherapeutic agents. In J. R. Thompson and B. W. Brown (eds.), Cancer Modelling. pp. 315-364. New York: Marcel Dekker.
15. Comandone, A., Leone, L., Oliva, C., Frustaci, S., Monteleone, M., Colussi, A. M., DalCanton, O., Bergnolo, P., Boglione, A. and Bumma, C. (1998). Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. Journal of Chemotherapy, 10, 385-393.
16. Curt, G. A.. Carney, D. M., Cowan, K. H., Jolivet, J., Bailey, B. D., Drake, J. C., Kao-Shan, C. W.. Minna, J. D. and Chabner, B. A. (1983). Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. New England Journal of Medicine, 308, 199-202.
17. Devonshire, A. L. and Field, L. M. (1991). Gene amplification and insecticide resistance. Annual Review of Entomology, 36, 1-23.
18. Donehower, R. C. (1990). Evaluating cancer chemotherapy by infusion. Journal of the National Cancer Institute, 82, 1867-1868.
19. Duk, H. N. and Nickolls, P. M. (1987). Multicompartment models of cancer chemotherapy incorporating resistant cell populations. Journal of Pharmacokinetics and Biopharmacology, 2, 145-177.
20. Eichholtz, H. and Trott, K. R. (1980). Effect of methotrexate concentration and exposure time on mammalian cell survival in vitro. British Journal of Cancer, 41, 277-284.
21. Evans, W. E. (1988). Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity. Blut, 56, 241-248.
22. Fabian, C. J., Kimler, B. F., McKittrick, R., Park, C. H.. Lin, F., Krishnan, L., Jewell, W. R., Osborne, C. K., Martino, S., Hutchins, L. F., Leong, L. A. and Green, S. (1994). Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancer - a Southwest Oncology Group Study. Cancer Research, 54, 5357-5362.
23. Farhangi, M. and Osserman, E. F. (1973). The treatment of multiple myeloma. Seminars in Hematology, 10, 149-161.
24. Frei, M. III. and Canellos, G. P. (1980). Dose: a critical factor in cancer chemotherapy. American Journal of Medicine, 69, 585-594.
25. Fulton, D.. Urtasun, R. and Forsyth, P. (1996). Phase-II study of prolonged oral-therapy with etoposide (VP16) for patients with recurrent malignant glioma. Journal of Clinical Oncology, 27, 149-155.
26. Gasparini, G., Pozza, F., Meli, S., Reitano, M., Santini, G. and Bevilacqua, P. (1991). Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness. Anticancer Research, 11, 2015-2022.
27. Gardner, S. N., Gressel, J. and Mangel, M. (1998). A revolving dose strategy to delay the evolution of both quantitative vs major monogene resistances to pesticides and drugs. International Journal of Pest Management, 44, 161-180.
28. Goldie, J.H. and Coldman, A.J. (1998). The biological basis of cancer and the problem of drug resistance. In Drug Resistance in Cancer, Mechanisms and Models. pp. 1-23. Cambridge: Cambridge University Press.
29. Goldie, J. H. and Coldman, A. J. (1984). The genetic origin of drug resistance in neoplasms: Implications for system therapy. Cancer Research, 44, 3643-3653.
30. Gressel, J., Gardner, S. N. and Mangel, M. (1996). Prevention Versus Remediation in Resistance Management. In T. M. Brown (ed.), Molecular Genetics and Evolution of Pesticide Resistance. pp. 169-186. Washington, D.C.: American Chemical Society.
31. Griswold, D. P., Trader, M. W., Frei, E. III., Peters, W. P., Wolpert, M. K. and Laster, W. R. Jr. (1987). Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy. Cancer Research, 47, 2323-2327.
32. Gyllenberg, M. and Webb, G. F. (1989). Quiescence as an explanation of Gompertzian tumor growth. Growth, Development & Aging, 53, 25-33.
33. Harnevo, L.E. and Agur, Z. (1991). The dynamics of gene amplification described as a multitype compartmental model and as a branching process. Mathematical Biosciences, 103, 115-138.
34. Harnevo, L. E. and Agur, Z. (1992). Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemotherapy and Pharmacology, 30, 469-476.
35. Hokanson, J. A., Brown, B. W., Thompson, J. R., Jansson, B. and Drewinko, B. (1986). Mathematical model for human myeloma relating growth kinetics and drug resistance. Cell and Tissue Kinetics, 19, 1-10.
36. Horns, R. C., Dower, W. J. and Schimke, R. T. (1984). Gene amplification in a leukemic patient treated with methotrexate. Journal of Clinical Oncology, 2, 1-7.
37. Hryniuk, W. (1995). Will increases in dose intensity improve outcome: pro. American Journal of Medicine, 99(6A), 69S-70S.
38. Joel, S. P., Ellis, P., O'Byrne, K., Papamichael, D., Hall, M., Penson, R., Nicholls, S., O'Donnell, C., Constantinou, A., Woodhull, J., Nicholson, M., Smith, I., Talbot, D. and Slevin, M. (1996). Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. Journal of Clinical Oncology, 14, 1903-1912.
39. Keefe, D. A., Capizzi, R. L. and Rudnick, S. A. (1982). Methotrexate cytotoxicity for L5178Y/Asn lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Research, 42, 1641-1645.
40. Kellen, J. A. (1994). Molecular interrelationships in multidrug resistance. Anticancer Research, 14, 433-436.
41. Kerbel, R. S. (1995). Impact of multicellular resistance on the survival of solid tumors, including micrometastases. Invasion Metastasis, 14, 50-60.
42. Kimler, B. F., Fabian, C. and Park, C. H. (1983). Stimulation of ER + breast cancer cells prior to administration of cell-cycle-specific chemotherapy. Cell and Tissue Kinetics, 16, 609.
43. Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., Mangalik, A. and Macdonald, J. S. (1995). Phase-II study of fluorouracil and its modulation in advanced colorectal-cancer - a Southwest-Oncology-Group Study. Journal of Clinical Oncology, 13, 1303-1311.
44. Livingston, R. B. (1994). Dose intensity and high dose therapy: Two different concepts. Cancer, 74, 1177-1183.
45. Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., Yosef, H., Habeshaw, T., Robertson, A. G., McInnes, A. and Twelves, C. J. (1998). Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation. British Journal of Cancer, 77, 1480-1486.
46. Manni, A., Santen, R. J., Boucher, A. E., Lipton, A., Harvey, H., Simmonds, M., Gordon, R., Rohner, T., Drago, J., Wettlaufer, J. and Glode, L. M. (1987). Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate-cancer. J. Steroid. Biochem., 27, 551-556.
47. Manni, A., Bartholomew, M., Caplan, R., Boucher, A., Santen, R., Lipton, A., Harvey, H., Simmonds, M., Whitehershey, D., Gordon, R., Rohner, T., Drago, J., Wettlaufer, J. and Glode, L. (1988). Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome. Journal of Clinical Oncology, 6, 1456-1466.
48. Marusic, M., Bajzer, Z., Freyer, J. P. and Vuk-Pavlovic, S. (1994). Analysis of growth of multicellular tumour spheroids by mathematical models. Cell Proliferation, 27, 73-94.
49. McArthur, J. R., Athens, J. W., Wintrobe, M. W. and Cartwright, G. E. (1970). Melphalan and myeloma. Experience with a low-dose continous regimen. Annals of Internal Medicine, 72, 665-670.
50. Meyer, J. S. (1989). Measurements of cellular Proliferation and DNA in breast carcinoma, In: J. Ragaz and I. M. Ariel (eds.), High-Risk Breast Cancer. pp. 141-171. Berlin: Springer Verlag.
51. Michelson. S. (1993). Mathematical models for multidrug resistance and its reversal. Cytotechnology, 12, 315-324.
52. Murray, J. M. (1995). An example of the effects of drug resistance on the optimal schedule for a single drug in cancer chemotherapy. IMA J. Math. Appl. Med. Biol., 12, 55-69.
53. Norton, L. and Simon, R. (1977). Tumor size, sensitivity to therapy, and design of treatments schedules. Cancer Treatment Reports, 61, 1307-1317.
54. Norton, L. and Simon, R. (1986). The Norton-Simon hypothesis revisited. Cancer Treatment Reports, 70, 163-169.
55. Pacciarini, M. A., Barbieri, B., Colombo, T., Massimo, B., Garattini, S. and Donelli, M. G. (1978). Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treatment Reports, 62, 791-800.
56. Panetta. J. C. (1998). A mathematical model of drug resistance: heterogeneous tumors. Mathematical Biosciences, 147, 41-61.
57. Paridaens, R., Heuson, J. C., Julien, J. P., Veyret, C., Van Zyl, J., Klijn, J. G. M., Sylvester, R. and Mignolet, F. (1993). Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. Journal of Clinical Oncologv, 11, 1723-1728.
58. Rath, H., Titsy, T. and Schimke, R. T. (1984). Rapid emergence of methotrexate resistance in cultured mouse cells. Cancer Research, 44, 3303-3306.
59. Rushing, D. A., Raber, S. R., Rodvold, K. A., Piscitelli, S. C., Plank, G. S. and Tewksbury, D. A. (1994). The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer (Phila.), 74, 834-841.
60. Sasaki, Y., Hakusui, H., Mizuno, S., Morita, M., Miya, T., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y. and Saijo, N. (1995). A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Japanese Journal of Cancer Research, 86, 101-110.
61. Schimke, R. T. (1984). Gene amplification, drug resistance, and cancer. Cancer Research, 44, 1735-1742.
62. Schimke, R. T., Hill, A. and Johnston, R. N. (1985). Methotrexate resistance and gene amplification: an experimental model for the generation of cellular heterogeneity. British Journal of Cancer, 51, 459-465.
63. Schoenlein, P. V. (1993). Molecular cytogenetics of multiple drug resistance. Cytotechnology, 12, 63-89.
64. Sikic, B. I.. Collins, J. M. and Mimnaugh, E. G. (1978). Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treatment Reports, 62, 2011-2017.
65. Simpson-Herren, L. and Lloyd, H. H. (1970). Kinetic parameters and growth curves for experimental tumor systems. Cancer Chemotherapy Reports, 54, 143-174.
66. Skipper, H. E., Schabel, F. M., Jr. and Wilcox, W. S. (1967). Experimental evaluation of potential anticancer agents. XXI, Scheduling or arabinosyl cytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemotherapy Reports, 51, 125-141.
67. Skipper, H. E., Schabel, F. M. and Lloyd, H. H. (1979). Doseresponse and tumor cell repopulation rate in chemotherapeutic trials. Advances in Cancer Chemotherapy, 1, 205-253.
68. Skubitz, K. M., Hamdan, H. and Thompson, R. C. Jr. (1993). Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer, 72, 2963-2969.
69. Sobrero, A. F., Aschele, C. and Bertino, J. R. (1997). Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation. Journal of Clinical Oncology, 15, 368-381.
70. Steel, G. G. (1977). Growth kinetics of tumours. Oxford: Clarendon Press.
71. Suarez, A. J., Lamm, D. L., Radsvin, H. M.. Sarodsy, M., Clark. G. and Osborne, C. K. (1982). Androgen priming and cyto-toxic chemotherapy in advanced prostatic cancer. Cancer Chemotherapy and Pharmacology, 8, 261-265.
72. Swan, G. W. (1990). Role of optimal control theory in cancer chemotherapy. Mathematical Biosciences, 101, 237-284.
73. Swan, G. W. and Vincent, T. L. (1977). Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bulletin of Mathematical Biology, 39, 317-337.
74. Toussaint, C., Izzo, J., Spielmann, M., Merle. S., Maylevin, F., Armand, J.P., Lacombe, D., Tursz, T., Sunderland, M., Chabot, G. G. and Cvitkovic, E. (1994). Phase I/II trial of continuous-infusion vinorelbine for advanced breast-cancer. Journal of Clinical Oncology, 12, 2102-2112.
75. Trent, J. M., Buck, R. N., Olson, S., Horns, R. C. Jr. and Schimke, R. T. (1984). Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma. Journal of Clinical Oncology, 2, 8-15.
76. Tsuruo, T. and Fidler, I. J. (1981). Differences in drug sensitivity among tumor-cells from parental tumors, selected variants, and spontaneous metastases. Cancer Research, 41, 3058-3064.
77. Ubezio, P., Tagliabue, G., Schechter, B. and Agur, Z. (1994). Increasing 1-β-D- Arabinofuranosylcytosine efficacy by scheduled dosing intervals based on direct measurements of bone marrow cell kinetics. Cancer Research, 54, 6446-6451.
78. vanPutten, L. M. (1974). Are cell kinetic data relevant for the design of tumour chemotherapy schedules? Cell Tissue Kinetics, 7, 493-504.
79. Watson, J. V. (1991). Tumour growth dynamics. British Medical Bulletin, 47, 47-63.
80. Wolmark, N., Piedbois, P., Rougier, P., Buyse, M., Pignon, J. P., Ryan, L., Hansen, R., Zee, B., Weinerman, B., Pater, J., Leichman, C., Macdonald, J., Benedetti, J., Lokich, J., Fryer, J., Brufman, G., Isacson, R., Laplanche, A., Levy, E., Harrington, D., McFadden, E., Ribble, A., Jacobson, R., Luboinski, M., Vaitkevicius, V., LeBourgeois, J. P., Piedbois, Y., Gauthier, E., DurandZaleski, I., Carlson, R., Rustum, Y. and Erlichman, C. (1998). Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Journal of Clinical Oncology, 16, 301-308.
81. Zalupski, M., Metch, B., Balcerzak, S., Fletcher, W. A. S., Chapman, R., Bonnet, J. D., et al. (1991). Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group Study. J. Natl. Cancer Inst., 83, 926-932.